Daewon Pharmaceutical Co., Ltd. (KRX:003220)
South Korea flag South Korea · Delayed Price · Currency is KRW
9,780.00
-760.00 (-7.21%)
Jun 10, 2026, 3:30 PM KST

Daewon Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
605,661605,435598,162526,952478,885354,176
Other Revenue
---0-0-0-0
605,661605,435598,162526,952478,885354,176
Revenue Growth (YoY)
1.31%1.22%13.51%10.04%35.21%14.81%
Cost of Revenue
333,887334,018312,188271,808243,038179,630
Gross Profit
271,773271,416285,974255,144235,847174,546
Selling, General & Admin
237,445233,974226,957198,507173,719144,585
Research & Development
25,39423,76221,92618,20712,646-
Amortization of Goodwill & Intangibles
2,1622,0992,0821,0341,505988.79
Other Operating Expenses
3,3693,3053,2422,9512,3208,009
Operating Expenses
273,312267,932259,297222,911192,943155,243
Operating Income
-1,5393,48426,67732,23342,90419,303
Interest Expense
-7,161-7,221-9,306-4,614-3,683-2,078
Interest & Investment Income
1,3281,2101,6641,4161,259532.2
Earnings From Equity Investments
822.56684.26704.2509.42860.08382.62
Currency Exchange Gain (Loss)
1,012251.34156.06121.26219.8271.59
Other Non Operating Income (Expenses)
-2,972-4,4551,354672.8823.15906.98
EBT Excluding Unusual Items
-8,509-6,04621,24930,33841,58319,119
Gain (Loss) on Sale of Investments
11,13510,788-1,149-61.5-752.76-870.39
Gain (Loss) on Sale of Assets
-386.33-583.17-19.83149.9545.71-0.86
Asset Writedown
-942.29-1,240-3,921-4,597-2,154-1,111
Other Unusual Items
-917.81-373.17----
Pretax Income
379.642,54516,15925,83038,72217,136
Income Tax Expense
5,4134,7496,0552,3678,06510,525
Earnings From Continuing Operations
-5,033-2,20410,10423,46330,6576,611
Earnings From Discontinued Operations
-1,958-1,809-1,059---
Net Income to Company
-6,991-4,0139,04523,46330,6576,611
Minority Interest in Earnings
2,6122,6335,165453.671,287378.15
Net Income
-4,380-1,38014,21023,91731,9446,989
Net Income to Common
-4,380-1,38014,21023,91731,9446,989
Net Income Growth
---40.59%-25.13%357.08%-60.38%
Shares Outstanding (Basic)
212121212121
Shares Outstanding (Diluted)
212121222221
Shares Change (YoY)
0.40%0.67%-1.71%-0.98%3.09%-0.58%
EPS (Basic)
-204.34-64.37667.431139.911509.75329.36
EPS (Diluted)
-227.35-87.38667.431110.441478.37329.36
EPS Growth
---39.90%-24.89%348.86%-60.15%
Free Cash Flow
13,15212,512-4,82939,44618,40518,309
Free Cash Flow Per Share
613.60583.77-226.831821.12841.34862.87
Dividend Per Share
250.000250.000---194.175
Dividend Growth
-----25.00%
Gross Margin
44.87%44.83%47.81%48.42%49.25%49.28%
Operating Margin
-0.25%0.58%4.46%6.12%8.96%5.45%
Profit Margin
-0.72%-0.23%2.38%4.54%6.67%1.97%
Free Cash Flow Margin
2.17%2.07%-0.81%7.49%3.84%5.17%
EBITDA
22,94027,23146,77149,79462,27237,109
EBITDA Margin
3.79%4.50%7.82%9.45%13.00%10.48%
D&A For EBITDA
24,47923,74720,09517,56119,36817,805
EBIT
-1,5393,48426,67732,23342,90419,303
EBIT Margin
-0.25%0.58%4.46%6.12%8.96%5.45%
Effective Tax Rate
1425.80%186.59%37.47%9.16%20.83%61.42%
Advertising Expenses
-35,37033,92329,70127,19926,272